Recently, Arvinas LLC (http://ir.arvinas.com/) reported that in a phase I clinical trial of prostate cancer, ARV-110 (NCT03888612 in Clinicaltrials.gov) [a PROTAC probe targeted to the androgen receptor (AR)] showed a good therapeutic effect, with DC50 values (the concentration at which 50% of the protein is degraded) of ~ 1 nM, and also demonstrated its safety and tolerability in patients with metastatic castration-resistant prostate cancer (mCRPC) [35, 36]. Here, AR is linked to Familial prostate cancer.